is this you? Claim your profile.
is this you? Claim your profile.
HQ Phone:  (212) 758-9700
Direct Phone: +44 ** **** ****
+ Get 10 Free Contacts a Month
It's free and takes 30 seconds
345 Park Avenue
New York City, New York,10154
KPMG LLP, the audit, tax and advisory firm, is the U.S. member firm of KPMG International Cooperative ("KPMG International"). KPMG is a global network of professional firms providing Audit, Tax and Advisory services. We operate in 155 countries and have more t... more.
Partner, Transaction Services
Millington is key participant in Chemical Week webcast focused on the M&A market | Millington
Join Chemicalweek Editor-in-Chief Rob Westervelt, Perstorp's chairman Lennart Holm, along with Rod Cantrill, Managing Director of M&A advisory group Millington Advisory Partners (London), and Chris Stirling, KPMG's Head of Chemicals as they share their knowledge on mergers, acquisitions, and effective restructuring.
Lennart Holm, Rod Cantrill, and Chris Stirling will help you avoid potential M&A failures by providing personal insights and best practice steps for undertaking acquisitions, significant restructuring activities, and working with acquirers.
Chris Stirling, Global Head of Life Sciences, KPMG.
Chris has held the role of Global Head of the Life Sciences division with KPMG since 2012. Chris was previously European Head of Chemicals and Pharmaceuticals at KPMG. B&M: Chris, you're the global Head of Life Sciences at KPMG, but can we start by understanding what that really equates to on a day to day basis and where you feel you add the greatest value in that role?
Divestments, such as this, are a recurring theme across the pharma M&A space and highlight the push to refocus and concentrate portfolios in particular therapeutic areas, says Chris Stirling, global head of life sciences at consultancy KPMG.
For instance, Merck & Co carved off its consumer health unit to Bayer at the end of last year, while GlaxoSmithKline and Novartis swapped oncology and vaccines portfolios earlier this year in a massive deal worth over $20 billion. Since then, GSK has sold its meningitis vaccines to Pfizer, its over-the-counter brands to Perrigo, its Australian opiates business to Sun Pharma, and even toyed with the idea of selling off a portfolio of older drugs and its stake in HIV firm ViiV Healthcare (which it later decided to retain). The result of divestment has lead to more focused companies with smaller overheads, says O'Keeffe. 'It has also left them with leaner R&D divisions, which is contributing to the increased need for deal making,' she adds. With all this activity, small companies and start-ups - especially those in the biotech space - are sitting pretty as they wait for suitors that are on the lookout for targets with potential breakthrough innovations, says Stirling. But it also means big pharma is likely to perform less R&D in-house, instead preferring to buy in products, says Stirling.
Chris Stirling is the global head of life sciences, Yael Selfin head of macroeconomics and Dr Lizzie Tuckey sector chief operating officer at consultancy firm KPMG UK.
January 2015 Drugs & Dealers Magazine Released | Biotech and Money
KEEPING PACE WITH A CHANGING HEALTHCARE LANDSCAPE - Chris Stirling, Global Head of Life Sciences, KPMG
21ST CENTURY FUNDING FOR 21ST CENTURY MEDICINES - Crowdcube, Cell Therapy Ltd. and KPMG